Identification	O
of	O
novel	O
1,2,3,6	B:C1254351
-	I:C1254351
tetrahydropyridyl	I:C1254351
-	I:C1254351
substituted	I:C1254351
benzo[d	I:C1254351
]	I:C1254351
thiazoles	I:C1254351
:	O
Lead	O
generation	I:C0242481
and	O
optimization	O
toward	O
potent	O
and	O
orally	O
active	O
EP1	O
receptor	I:C2936364
antagonists	O
.	O

Identification	O
of	O
novel	O
1,2,3,6	O
-	I:C1254351
tetrahydropyridyl	I:C1254351
-	I:C1254351
substituted	I:C1254351
benzo[d	I:C1254351
]	I:C1254351
thiazoles	I:C1254351
:	O
Lead	B:C0242481
generation	I:C0242481
and	O
optimization	O
toward	O
potent	O
and	O
orally	O
active	O
EP1	O
receptor	I:C2936364
antagonists	O
.	O

Identification	O
of	O
novel	O
1,2,3,6	O
-	I:C1254351
tetrahydropyridyl	I:C1254351
-	I:C1254351
substituted	I:C1254351
benzo[d	I:C1254351
]	I:C1254351
thiazoles	I:C1254351
:	O
Lead	O
generation	I:C0242481
and	O
optimization	O
toward	O
potent	O
and	O
orally	O
active	O
EP1	B:C2936364
receptor	I:C2936364
antagonists	O
.	O

Identification	O
of	O
novel	O
1,2,3,6	O
-	I:C1254351
tetrahydropyridyl	I:C1254351
-	I:C1254351
substituted	I:C1254351
benzo[d	I:C1254351
]	I:C1254351
thiazoles	I:C1254351
:	O
Lead	O
generation	I:C0242481
and	O
optimization	O
toward	O
potent	O
and	O
orally	O
active	O
EP1	O
receptor	I:C2936364
antagonists	B:C1373004
.	O

Herein	O
we	O
described	O
the	O
design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
a	O
novel	O
series	O
of	O
benzo[d	B:C1254351
]	I:C1254351
thiazole	I:C1254351
derivatives	I:C1254351
toward	O
an	O
orally	O
active	O
EP1	O
antagonist	O
.	O

Herein	O
we	O
described	O
the	O
design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
a	O
novel	O
series	O
of	O
benzo[d	O
]	I:C1254351
thiazole	I:C1254351
derivatives	I:C1254351
toward	O
an	O
orally	O
active	O
EP1	B:C2936364
antagonist	O
.	O

Herein	O
we	O
described	O
the	O
design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
a	O
novel	O
series	O
of	O
benzo[d	O
]	I:C1254351
thiazole	I:C1254351
derivatives	I:C1254351
toward	O
an	O
orally	O
active	O
EP1	O
antagonist	B:C1373004
.	O

Lead	B:C0242481
generation	I:C0242481
studies	I:C0242481
provided	O
benzo[	O
d	O
]	O
thiazole	O
core	O
from	O
the	O
four	O
designed	O
scaffolds	O
.	O

Optimization	O
of	O
this	O
scaffold	O
in	O
terms	O
of	O
EP1	B:C2936364
antagonist	O
potency	O
and	O
ligand	O
-	O
lipophilicity	O
efficiency	O
(	O
LLE	O
;	O
pIC50	O
-	O
clogP	O
)	O
led	O
to	O
a	O
1,2,3,6-	O
tetrahydropyridyl	I:C1254351
-	I:C1254351
substituted	I:C1254351
benzo[d	I:C1254351
]	I:C1254351
thiazole	I:C1254351
derivative	I:C1254351
,	I:C1254351
7r	I:C1254351
(	O
IC50	O
1.1	O
nM	O
;	O
LLE	O
4.7	O
)	O
,	O
which	O
showed	O
a	O
good	O
pharmacological	O
effect	O
when	O
administered	O
intraduodenally	O
in	O
a	O
17	O
-	I:C0295046
phenyl	I:C0295046
trinor	I:C0295046
-	I:C0295046
PGE2	I:C0295046
(	O
17	O
-	I:C0295046
phenyl	I:C0295046
trinor	I:C0295046
-	I:C0295046
PGE2	I:C0295046
)	O
-	O
induced	O
overactive	O
bladder	I:C0878773
model	O
in	O
rats	O
.	O

Optimization	O
of	O
this	O
scaffold	O
in	O
terms	O
of	O
EP1	O
antagonist	B:C1373004
potency	O
and	O
ligand	O
-	O
lipophilicity	O
efficiency	O
(	O
LLE	O
;	O
pIC50	O
-	O
clogP	O
)	O
led	O
to	O
a	O
1,2,3,6-	O
tetrahydropyridyl	I:C1254351
-	I:C1254351
substituted	I:C1254351
benzo[d	I:C1254351
]	I:C1254351
thiazole	I:C1254351
derivative	I:C1254351
,	I:C1254351
7r	I:C1254351
(	O
IC50	O
1.1	O
nM	O
;	O
LLE	O
4.7	O
)	O
,	O
which	O
showed	O
a	O
good	O
pharmacological	O
effect	O
when	O
administered	O
intraduodenally	O
in	O
a	O
17	O
-	I:C0295046
phenyl	I:C0295046
trinor	I:C0295046
-	I:C0295046
PGE2	I:C0295046
(	O
17	O
-	I:C0295046
phenyl	I:C0295046
trinor	I:C0295046
-	I:C0295046
PGE2	I:C0295046
)	O
-	O
induced	O
overactive	O
bladder	I:C0878773
model	O
in	O
rats	O
.	O

Optimization	O
of	O
this	O
scaffold	O
in	O
terms	O
of	O
EP1	O
antagonist	O
potency	O
and	O
ligand	O
-	O
lipophilicity	O
efficiency	O
(	O
LLE	O
;	O
pIC50	O
-	O
clogP	O
)	O
led	O
to	O
a	O
1,2,3,6-	B:C1254351
tetrahydropyridyl	I:C1254351
-	I:C1254351
substituted	I:C1254351
benzo[d	I:C1254351
]	I:C1254351
thiazole	I:C1254351
derivative	I:C1254351
,	I:C1254351
7r	I:C1254351
(	O
IC50	O
1.1	O
nM	O
;	O
LLE	O
4.7	O
)	O
,	O
which	O
showed	O
a	O
good	O
pharmacological	O
effect	O
when	O
administered	O
intraduodenally	O
in	O
a	O
17	O
-	I:C0295046
phenyl	I:C0295046
trinor	I:C0295046
-	I:C0295046
PGE2	I:C0295046
(	O
17	O
-	I:C0295046
phenyl	I:C0295046
trinor	I:C0295046
-	I:C0295046
PGE2	I:C0295046
)	O
-	O
induced	O
overactive	O
bladder	I:C0878773
model	O
in	O
rats	O
.	O

Optimization	O
of	O
this	O
scaffold	O
in	O
terms	O
of	O
EP1	O
antagonist	O
potency	O
and	O
ligand	O
-	O
lipophilicity	O
efficiency	O
(	O
LLE	O
;	O
pIC50	O
-	O
clogP	O
)	O
led	O
to	O
a	O
1,2,3,6-	O
tetrahydropyridyl	I:C1254351
-	I:C1254351
substituted	I:C1254351
benzo[d	I:C1254351
]	I:C1254351
thiazole	I:C1254351
derivative	I:C1254351
,	I:C1254351
7r	I:C1254351
(	O
IC50	O
1.1	O
nM	O
;	O
LLE	O
4.7	O
)	O
,	O
which	O
showed	O
a	O
good	O
pharmacological	O
effect	O
when	O
administered	O
intraduodenally	O
in	O
a	O
17	B:C0295046
-	I:C0295046
phenyl	I:C0295046
trinor	I:C0295046
-	I:C0295046
PGE2	I:C0295046
(	O
17	O
-	I:C0295046
phenyl	I:C0295046
trinor	I:C0295046
-	I:C0295046
PGE2	I:C0295046
)	O
-	O
induced	O
overactive	O
bladder	I:C0878773
model	O
in	O
rats	O
.	O

Optimization	O
of	O
this	O
scaffold	O
in	O
terms	O
of	O
EP1	O
antagonist	O
potency	O
and	O
ligand	O
-	O
lipophilicity	O
efficiency	O
(	O
LLE	O
;	O
pIC50	O
-	O
clogP	O
)	O
led	O
to	O
a	O
1,2,3,6-	O
tetrahydropyridyl	I:C1254351
-	I:C1254351
substituted	I:C1254351
benzo[d	I:C1254351
]	I:C1254351
thiazole	I:C1254351
derivative	I:C1254351
,	I:C1254351
7r	I:C1254351
(	O
IC50	O
1.1	O
nM	O
;	O
LLE	O
4.7	O
)	O
,	O
which	O
showed	O
a	O
good	O
pharmacological	O
effect	O
when	O
administered	O
intraduodenally	O
in	O
a	O
17	O
-	I:C0295046
phenyl	I:C0295046
trinor	I:C0295046
-	I:C0295046
PGE2	I:C0295046
(	O
17	B:C0295046
-	I:C0295046
phenyl	I:C0295046
trinor	I:C0295046
-	I:C0295046
PGE2	I:C0295046
)	O
-	O
induced	O
overactive	O
bladder	I:C0878773
model	O
in	O
rats	O
.	O

Optimization	O
of	O
this	O
scaffold	O
in	O
terms	O
of	O
EP1	O
antagonist	O
potency	O
and	O
ligand	O
-	O
lipophilicity	O
efficiency	O
(	O
LLE	O
;	O
pIC50	O
-	O
clogP	O
)	O
led	O
to	O
a	O
1,2,3,6-	O
tetrahydropyridyl	I:C1254351
-	I:C1254351
substituted	I:C1254351
benzo[d	I:C1254351
]	I:C1254351
thiazole	I:C1254351
derivative	I:C1254351
,	I:C1254351
7r	I:C1254351
(	O
IC50	O
1.1	O
nM	O
;	O
LLE	O
4.7	O
)	O
,	O
which	O
showed	O
a	O
good	O
pharmacological	O
effect	O
when	O
administered	O
intraduodenally	O
in	O
a	O
17	O
-	I:C0295046
phenyl	I:C0295046
trinor	I:C0295046
-	I:C0295046
PGE2	I:C0295046
(	O
17	O
-	I:C0295046
phenyl	I:C0295046
trinor	I:C0295046
-	I:C0295046
PGE2	I:C0295046
)	O
-	O
induced	O
overactive	B:C0878773
bladder	I:C0878773
model	O
in	O
rats	O
.	O

Optimization	O
of	O
this	O
scaffold	O
in	O
terms	O
of	O
EP1	O
antagonist	O
potency	O
and	O
ligand	O
-	O
lipophilicity	O
efficiency	O
(	O
LLE	O
;	O
pIC50	O
-	O
clogP	O
)	O
led	O
to	O
a	O
1,2,3,6-	O
tetrahydropyridyl	I:C1254351
-	I:C1254351
substituted	I:C1254351
benzo[d	I:C1254351
]	I:C1254351
thiazole	I:C1254351
derivative	I:C1254351
,	I:C1254351
7r	I:C1254351
(	O
IC50	O
1.1	O
nM	O
;	O
LLE	O
4.7	O
)	O
,	O
which	O
showed	O
a	O
good	O
pharmacological	O
effect	O
when	O
administered	O
intraduodenally	O
in	O
a	O
17	O
-	I:C0295046
phenyl	I:C0295046
trinor	I:C0295046
-	I:C0295046
PGE2	I:C0295046
(	O
17	O
-	I:C0295046
phenyl	I:C0295046
trinor	I:C0295046
-	I:C0295046
PGE2	I:C0295046
)	O
-	O
induced	O
overactive	O
bladder	I:C0878773
model	O
in	O
rats	B:C0034693
.	O

